T
Tenaya Therapeutics
Dedicated to discovering and developing novel therapies for heart failures
About Tenaya Therapeutics
Tenaya Therapeutics is a biopharmaceutical company focused on discovering, developing, and delivering potentially curative therapies for heart disease. The company operates in the healthcare and biotechnology market, primarily serving patients suffering from various forms of heart disease. Tenaya's business model revolves around leveraging advanced scientific research and precision medicine to create innovative treatments that address the underlying causes of heart conditions. The company generates revenue through the development and commercialization of its therapeutic products, which are currently in various stages of preclinical and clinical development. Tenaya Therapeutics aims to transform the lives of individuals and families affected by heart disease by offering groundbreaking solutions that go beyond symptom management to target the root causes of the condition.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- San Francisco, United States
- Listing
- IPO 2021
- Employees
- 96
- Open positions
- None listed
- Dealroom signal
- 64.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Precision Medicine, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Tenaya Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Dec 2025 | $0 | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Mar 2025 | $53M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $8.5M | — | −$89M | -1049.2% |
| 2025 | $0 | — | −$85M | — |
| 2024 | $0 | — | −$107M | — |
| 2023 | $0 | — | −$123M | — |
| 2022 | $0 | — | −$126M | — |
| 2021 | $0 | — | −$73M | — |
| 2020 | $0 | — | −$36M | — |
Growth signals
Latest recorded traffic for Tenaya Therapeutics is 6.1K monthly website visits, down 17.6% over the last three months. Tenaya Therapeutics's team declined 10.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
The Column Group
Casdin Capital
GV
Series B and later11 investors entered at this stage
RTW Investments
Fidelity Investments
T. Rowe Price
RA Capital Management
Venrock
Integra Health Management
BlackRock
PFM Health Sciences
Octagon Capital Partners- SCSoleus Capital
Armistice Capital
Other known investors1 additional known investor
University of California, Berkeley
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tenaya Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tenaya Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.